CN107412249A - Cordycepin is preparing the application in suppressing tumour medicine - Google Patents
Cordycepin is preparing the application in suppressing tumour medicine Download PDFInfo
- Publication number
- CN107412249A CN107412249A CN201710765398.1A CN201710765398A CN107412249A CN 107412249 A CN107412249 A CN 107412249A CN 201710765398 A CN201710765398 A CN 201710765398A CN 107412249 A CN107412249 A CN 107412249A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- cell
- medicine
- leukaemia
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of the cordycepin in suppression tumour medicine is prepared, tumour includes leukaemia.The advantage of the invention is that the medicine in the suppression tumour of its preparation can preferably treat tumor patient, and the adverse reaction of patient can be reduced, be laid a good foundation for final tumor patient of curing.
Description
Technical field
The invention belongs to medical domain, and in particular to cordycepin is preparing the application in suppressing tumour medicine.
Background technology
Leukaemia is malignant tumour of the more typical generation in all age group.At present to the primary treatments of leukaemia
It is bone-marrow transplantation and chemotherapy, but chemotherapeutics often has very strong side effect, while also destroy the immune system of human body.
So a kind of less medicine of side effect, patient can also be reduced by being not only able to the anti-tumour including leukaemia
Pain is that very have practical value.
The content of the invention
In order to overcome the above-mentioned deficiencies of the prior art, the answering in suppression tumour medicine is prepared the invention provides cordycepin
With.
Application of the cordycepin provided by the invention in suppression tumour medicine is prepared, described tumour include leukaemia.
The advantage of the invention is that the medicine in the suppression tumour of its preparation can preferably treat tumor patient, and can subtract
The adverse reaction of few patient, laid a good foundation for final tumor patient of curing.
Brief description of the drawings：
Figure 1A-J show that cordycepin can suppress the propagation of leukaemia；
Fig. 2A-I show that cordycepin can promote the apoptosis of leukaemia.
Embodiment
Cordycepin is a kind of analog of the adenosine extracted from Cordyceps militaris, and it is originally that one kind is widely used in immunological regulation
The Chinese medicine preparation of effect.The present invention is further described with reference to specific embodiment, to more fully understand the present invention.
Embodiment 1：The implementation steps of influence of the cordycepin to leukaemia's THP-1 cell viabilities.
In vitro culture Leukemia Cell Lines THP-1.Take the logarithm the phase growth THP-1 cells, with 300g centrifuge 5min.Centrifugation
After remove supernatant, be resuspended with Phorbol-12-myristate-13-acetate containing 100nM (PMA) complete medium thin
Born of the same parents, and count.By cell with the quantity kind in 20000/hole into 96 orifice plates.Next day adds the worm of respective concentration after cell kind plate
Careless element, the concentration of cordycepin is respectively 0,25,50,100,150,200 μM/L.Three multiple holes of each concentration, detection time point are
0h, 24h, 48h, 72h and 96h.
CCK-8 detection kits are used in cell viability detection.First with 1:10 ratio is matched somebody with somebody with the complete mediums of RPMI 1640
Appropriate CCK-8 solution is put, the THP-1 cells after dosing are taken into a plate, the nutrient solution in cell are changed the CCK-8 just configured
Solution, 110 μ l/ holes.It is placed in incubator and is incubated 2.5h.The cell for adding CCK-8 is taken out after 2.5h, removes bubble in hole,
It is put into the absorbance that 450nm is measured in ELIASA.The cell for detecting leukaemia after 0h, 24h, 48h, 72h and 96h successively is lived
Power.Cell viability calculation formula is：(24h/48h/72h/96h treatment groups absorbance -0h treatment groups absorbance)/(24h/48h/
72h/96h non-process group absorbance -0h non-process groups absorbance).
As a result as shown in figure 1, Figure 1A-F, which are CCK-8 methods, detects influence of the cordycepin to leukaemia cell vigor.Figure
1G-1J is influence of the cordycepin to the cell viability of THP-1 leukaemia, it can be seen that it is thin that cordycepin can suppress leukaemia
The activity of born of the same parents, and be in concentration dependent and time dependence.Therefore, cordycepin can suppress the propagation of leukaemia.
Embodiment 2：The implementation steps of influence of the cordycepin to apoptosis of leukemia.
1. apoptosis induction
Take the logarithm the phase growth THP-1 cells, with 300g centrifuge 5min.Supernatant is removed after centrifugation, it is complete with RPMI1640
Culture medium is resuspended cell and counted.By cell with 2 × 105Into 6 orifice plates, the concentration of cordycepin is respectively the quantity kind in individual/hole
0,25,50,100,150,200 μM/L, every group sets three multiple holes.
2. apoptosis detects
Cell is collected, cell suspension is collected into streaming pipe.Carefully remove streaming Guan Zhongpei after 1500rpm centrifugations 5min
Base is supported, adds the PBS washing cell of precooling, and 5min is centrifuged with 1500rpm again.Carefully outwell in streaming pipe
Clearly, by AlexaV/PI of Annexin kits explanation adds 100 1 × combination buffers of μ l (binding buffer)
With 5 μ l AlexaThe dyeing liquors of annexin V mix, and are incubated at room temperature 15min；It is eventually adding the μ g/ml of 1 μ l 100 PI works
Make dyeing liquor, add 400 1 × combination buffers of μ l (binding buffer), and streaming pipe is placed on ice.Use streaming
Cell instrument detection cell combination Annexin V and PI situation.
Fig. 2 is final result, and Fig. 2A -2F are FCM analysis of the various concentrations cordycepin to apoptosis of leukemia
As a result.For Fig. 2A -2F, apoptotic cell ratio is counted in Fig. 2 G-2I, as illustrated, early apoptosis and late period
The ratio of apoptotic cell increases with the increase of cordycepin concentration, and has statistical significance.As can be seen here, cordycepin can
Inducing leukemia apoptosis, and be in concentration dependent.
The embodiment of the present invention shows that the medicine of the suppression tumour prepared with cordycepin can preferably treat tumor patient, and
The adverse reaction of patient can be reduced, is laid a good foundation for final tumor patient of curing.
The specific embodiment of the present invention is described in detail above, but it is intended only as example, it is of the invention and unlimited
It is formed on particular embodiments described above.To those skilled in the art, it is any to the equivalent modifications that carry out of the present invention and
Substitute also all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and
Modification, all should be contained within the scope of the invention.
Claims (1)
1. cordycepin is preparing the application in suppressing tumour medicine, it is characterised in that described tumour includes leukaemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710765398.1A CN107412249A (en) | 2017-08-30 | 2017-08-30 | Cordycepin is preparing the application in suppressing tumour medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710765398.1A CN107412249A (en) | 2017-08-30 | 2017-08-30 | Cordycepin is preparing the application in suppressing tumour medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107412249A true CN107412249A (en) | 2017-12-01 |
Family
ID=60435261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710765398.1A Pending CN107412249A (en) | 2017-08-30 | 2017-08-30 | Cordycepin is preparing the application in suppressing tumour medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107412249A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574362A (en) * | 2009-06-03 | 2009-11-11 | 西南大学 | Application of N-alkanoyl cordycepin in preparing drugs for treating tumor diseases |
| CN103622934A (en) * | 2013-11-13 | 2014-03-12 | 青海互丰农业科技集团有限公司 | Sustained-release cordycepin capsule and preparation method thereof |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
| CN106798725A (en) * | 2015-11-26 | 2017-06-06 | 王春梅 | A kind of cordycepin nano liposomes and preparation method thereof and antitumor activity application |
-
2017
- 2017-08-30 CN CN201710765398.1A patent/CN107412249A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574362A (en) * | 2009-06-03 | 2009-11-11 | 西南大学 | Application of N-alkanoyl cordycepin in preparing drugs for treating tumor diseases |
| CN103622934A (en) * | 2013-11-13 | 2014-03-12 | 青海互丰农业科技集团有限公司 | Sustained-release cordycepin capsule and preparation method thereof |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
| CN106798725A (en) * | 2015-11-26 | 2017-06-06 | 王春梅 | A kind of cordycepin nano liposomes and preparation method thereof and antitumor activity application |
Non-Patent Citations (1)
| Title |
|---|
| 专题报道: "虫草素的开发和利用", 《中国科技产业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106977403B (en) | A kind of compound and the preparation method and application thereof with anticancer activity | |
| CN104593326A (en) | Method for preparing enhanced DC-CIK cell induced by traditional Chinese medicines and application of enhanced DC-CIK cells induced by traditional Chinese medicines | |
| Wang et al. | The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism | |
| CN105087488A (en) | Preparation method and application of DC-CIK cell induced by tumor antigen | |
| CN103966164A (en) | Preparation method of hemizygote CAPRI cells | |
| CN103865874A (en) | CIK cell, and preparation method and application thereof | |
| Bhargav et al. | Enhancement of cancer stem cell susceptibility to conventional treatments through complementary yoga therapy: possible cellular and molecular mechanisms | |
| Xiao et al. | High‐dose wogonin exacerbates DSS‐induced colitis by up‐regulating effector T cell function and inhibiting Treg cell | |
| CN107412249A (en) | Cordycepin is preparing the application in suppressing tumour medicine | |
| CN104352521B (en) | Prepare the method for calf spleen extract and the application in antitumor and immunological regulation | |
| CN107485609A (en) | Dihydroartemisinine is preparing the application in suppressing tumour medicine | |
| Zhao et al. | Protective effects and mechanism of coenzyme Q10 and vitamin C on doxorubicin-induced gastric mucosal injury and effects of intestinal flora | |
| Wang et al. | Experimental study on inhibition of S180 tumor cells by Agrimonia pilosa extract | |
| Liu et al. | Gut microbiome, metabolome and alopecia areata | |
| Li et al. | Relationship between endogenous hydrogen sulfide and blood stasis syndrome based on the Qi-blood theory of chinese medicine | |
| CN101429496A (en) | Culture medium for human peripheral blood source hemopoietic stem cell | |
| CN101429495A (en) | Cultivation method for human peripheral blood source hemopoietic stem cell | |
| CN115300522A (en) | Application of Weissella cibaria D-2 exopolysaccharide in inhibition of human colon cancer cells | |
| CN103948926A (en) | Use of miR-9 inhibitor in preparation of tumor growth inhibition drugs | |
| Li et al. | Akt promotes irradiation-induced regulatory T-cell survival in hepatocellular carcinoma | |
| CN108478557A (en) | Application of the atractylenolide Ⅰ in preparing medicines resistant to liver cancer | |
| Zhijun et al. | The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice | |
| CN103897050B (en) | A kind of squid ink anti-prostate cancer polypeptide and preparation method thereof | |
| CN104147355B (en) | A kind of antitumor injection liquor and preparation method thereof | |
| CN110840884A (en) | Application of prodigiosin in preparation of cell proliferation inhibitor for lymphangiomatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171201 |